ライフサイエンスコーパス: case analysis

1 s 23 of 161 participants [14.3%] in complete-case analysis).

2 thout replacing the missing values (observed-cases analysis).

3 $1042.5 million-$1637.5 million) in the base case analysis.

4 tient hospital setting was used for the base-case analysis.

5 ma Drynariae (RD) and Lycii Fructus (LF)-for case analysis.

6 NA functional similarity network and perform case analysis.

7 ses included best case analysis and complete case analysis.

8 inated by TNT with selective NOM in the base case analysis.

9 -tailed P values were calculated for failure case analysis.

10 R) of each strategy was calculated in a base case analysis.

11 ing area of Wudong Coal Mine for engineering case analysis.

12 for repeated measures and involving complete case analysis.

13 .8% and 18.3%, respectively, in the complete case analysis.

14 ks after drug administration using available case analysis.

15 ICERs (up to 4.2-fold) in conservative base-case analysis.

16 patient over 2-year time horizon at the base case analysis.

17 nd increase precision compared with complete-case analysis.

18 We did a completed case analysis.

19 esions was evaluated with a leave-one-out-by-case analysis.

20 ion in a 30-year-old male was used as a base case analysis.

21 of the cases were excluded from the complete case analysis.

22 th a missing covariate to perform a complete case analysis.

23 in so-called "complete records" or "complete case" analysis.

24 and were included in the principal complete-cases analysis.

25 ary analysis was selected a priori: complete case analysis, 1-to-1 practice matching, up to 5 control

26 In the base-case analysis, 11,646,000 persons in the US would be scr

27 ared using 4 different missing-data complete-case analysis, 2 multiple-imputation models, and nearest

28 to handle missing outcome data: 1) complete case analysis; 2) single imputation; and 3) multiple imp

29 -completions were investigated: (1) complete case analysis; (2) proxy substitution; (3) Method 2 plus

30 arm than in the control arm in the complete-case analysis (4.0 [4.3] vs 5.0 [4.7]; adjusted differen

31 In the base case analysis, 6-month total costs varied from $14 590 (

32 roup (mean adjusted difference with complete case analysis, 8.0 points; 95% confidence interval [CI],

33 The case analysis addresses the question of whether the scaf

34 es included probabilistic analysis, complete case analysis, adjustment of key unit prices, and a hosp

35 d for mortality (aHR 0.53, p=0.004; complete case analysis: aHR 0.39, p<0.001 excluding "not reported

36 In the base-case analysis, all strategies for influenza vaccination

37 In the base case analysis, anakinra was the least effective and leas

38 Estimates from complete-case analysis and a per-protocol analysis were similar t

39 Results were comparable in the complete case analysis and adverse effects were similar between g

40 Post hoc sensitivity analyses included best case analysis and complete case analysis.

41 Complete-case analysis and extended TMLE had small biases when ou

42 roups was not significant, both for complete case analysis and multiple imputation analysis.

43 test, with analyses conducted using complete case analysis and multiple imputation.

44 with the level of agreement between complete case analysis and the true data (ICC = 0.93 and kappa =

45 el for location, shape, and scale), complete-case analysis, and multiple imputation in a simulation s

46 missing data as smoking (primary), complete case analysis, and multiple imputation.

47 Intention-to-treat analysis, completers case analysis, and sensitivity analysis were additionall

48 Results: In the base-case analysis, annual combined screening was most effect

49 In base-case analysis, antimicrobial lock solutions resulted in

50 -protocol, treatment adherence, and complete case analysis approaches.

51 The source code of MATTE and case analysis are available at

52 te-stratified effect estimates from complete-case analysis are unbiased when missingness is independe

53 ant-factor approximation guarantees in worst-case analysis, as opposed to the much coarser additive-e

54 The base-case analysis assumed continuous use of a HEPA filter.

55 The base case analysis assumed modest benefits of earlier detecti

56 The base case analysis assumed that a hospital with an existing l

57 Base-case analysis at a genotyping cost of $70 produced an in

58 In the primary (complete-case) analysis at 144 weeks, 317 (86%) of 367 in the pro

59 Results of Base-Case Analysis: At 10 years, scale-back strategies increa

60 A complete-case analysis based on all 3 SNPs was found to be more p

61 using a structured qualitative method (cross-case analysis based on predefined categories and develop

62 The primary analysis was a complete-case analysis based on the intention-to-treat population

63 In the base-case analysis BOC-RVR and TVR-IL28B strategies were the

64 In complete case analysis, bromocriptine treatment was associated wi

65 Furthermore, we perform a study case analysis by applying our pipeline to forecast blood

66 Results of Base-Case Analysis: By reducing incidence and severity of her

67 Results of Base-Case Analysis: Clinically important HTEs could explain d

68 In the base-case analysis, compared with no additional intervention,

69 In 1 base-case analysis, compliance was assumed to be 60% with the

70 In the base-case analysis, costs from the French National Insurance

71 In the observed case analysis, cough frequency was reduced by 75% when p

72 In the base-case analysis dose-adjusted sorafenib was the most effec

73 In case-case analysis, EBV(+) disease was significantly associat

74 This retrospective case analysis evaluated the feasibility and activity of

75 ssing-data methods in this context: complete-case analysis, extended TMLE incorporating an outcome-mi

76 Results of Base-Case Analysis: FIT screening without surveillance reduce

77 Base-case analysis focused on patients with average-risk brea

78 Here, we assess the bias of complete-case analysis for adjusted marginal effects when confoun

79 lity ratios were estimated based on complete case analysis for the base case analysis, where only pat

80 In the base case analysis for the Netherlands (mean RSV incidence, 3

81 In the base-case analysis for the voluntary screening program, overa

82 Base case analysis found DSAEK to be less costly compared wit

83 justed life year was pound56,811 in the base case analysis from a National Health Service perspective

84 We performed the base-case analysis from the societal perspective with a willi

85 Measurements and Main Results: In the base-case analysis, HEPA filter use resulted in increased cos

86 : Participants were included in the complete case analysis if they had initiated at least 1 follow-up

87 In the base-case analysis, if CTC were used as the primary modality

88 In the base-case analysis, if in-hospital advance care planning and

89 Results of Base-Case Analysis: Immediate access to OAT for all treatment

90 The base case analysis in a cohort of 1763 patients undergoing ca

91 In a base-case analysis in which compliance with screening and fol

92 In a complete-case analysis in which data were not available for 23 pa

93 The complete-case analysis included 257 patients.

94 Our complete case analysis included 600,484 adults from 45 countries.

95 The base-case analysis included a hypothetical cohort of 60-year-

96 The base-case analysis included all study site-specific resource

97 Base-case analysis indicated no differences in costs or QALYs

98 The base-case analysis indicated that GAM had an INMB of $599 in

99 A case-by-case analysis indicated that misses and false-positive r

100 Results of Base-Case Analysis: Individualized control saved $13 547 per

101 Complete-case analysis is commonly used in epidemiologic analyses

102 The reference case analysis is conducted from the societal perspective

103 s to deal with them are rare, and a complete-case analysis is the norm.

104 bias of 5 methods used in practice: complete-case analysis, last observation carried forward, the mis

105 In the base case analysis, LVAD yielded an additional 3.45 QALYs at

106 Besides the complete case analysis, multiple imputation analysis was performe

107 In a multivariable complete case analysis (n = 371 [92.9%]) adjusting for potential

108 In an exact-matched case analysis (n = 38), median survival time for RSR13 p

109 Complete case analysis (n = 48) on the main outcome showed reduce

110 population-standardised results for the base case analysis, national bans produced cost-effectiveness

111 count for missing outcome data were complete case analysis, nonresponder imputation, last observation

112 eat analysis and retention weighted complete case analysis of 30-day and 7-day ppa.

113 in the extractive industries, and empirical case analysis of 50 projects worldwide, this research re

114 This is the largest case analysis of MTT and one of the few to document an i

115 Retrospective case analysis of patients with surgical repair of open g

116 be strongly regulated, as well as by case-by-case analysis of the genes on the basis of expert domain

117 A complete case analysis of the outcome of kidney-only transplants

118 ephrotic syndrome requires a careful case-by-case analysis of the risks for thromboembolic events bal

119 The base-case analysis of the trial-based economic evaluation sho

120 This is the first in-depth multiple case analysis of VF on LA CAB/RPV therapy in a real-worl

121 tron-exon splice regions of KEL and, in some cases, analysis of mRNA transcripts and expression of mu

122 ndard ad hoc practice is to perform complete case analysis or imputation prior to model fitting.

123 d with disease-specific survival in the full case analysis or in the stage-stratified analyses.

124 ared error than those obtained with complete-case analysis or multiple imputation.

125 cluding patients with missing data (complete case analysis), or (3) excluding the predictor with miss

126 In the base-case analysis, patients with structural valve deteriorat

127 Results of Base-Case Analysis: PrEP+screen+ART dominates other strategie

128 Compared with multiple imputation, complete case analysis produced different association magnitudes

129 This case analysis raises several concerns: risks of vermicul

130 Using the conventional complete case analysis (responders only), high-intensity cessatio

131 Case analysis revealed Mixtral's superior handling of in

132 Individual case analysis revealed that subtle changes in language w

133 g a PASI of 2 or lower (PS-weighted complete case analysis: RR, 1.28 [95% CI, 1.06-1.55]; RD, 11.9% [

134 The base case analysis showed acupuncture to be marginally more e

135 A case-case analysis showed association of infection with the o

136 Complete case analysis suggests both therapies are cost-effective

137 Worst-case analysis suggests that THA remains minimally cost-e

138 hile supporting GWAS validation and clinical case analysis tasks.

139 In our base-case analysis, TAVR was projected to be an economically

140 epression at 6 months (prespecified complete-case analysis), testing for noninferiority of the interv

141 factors on survival, we assumed in our base-case analysis that 50 percent of the gains were due to m

142 In the complete case analysis the absolute risk difference for the occur

143 In the base case analysis, the addition of necitumumab to the treatm

144 In the base-case analysis, the cost associated with the infectious d

145 For the Italian base-case analysis, the cost-effective ICER obtained using po

146 For the base case analysis, the expected cost of providing stress ulc

147 In the base-case analysis, the HCPIA program yielded 8.42 discounted

148 For the base-case analysis, the incremental cost per quality-adjusted

149 In the base case analysis, the intervention was dominant, with mean

150 In the base-case analysis, the net cost per DALY averted was $833 co

151 In the base-case analysis, the Newhints intervention cost a mean of

152 r recommendations constituting the reference case analysis, the set of practices developed to guide C

153 Results of Base-Case Analysis: The sacubitril-valsartan group experience

154 Results of Base-Case Analysis: The within-trial analysis found that etan

155 ion of unbiased marginal effects in complete-case analysis therefore requires close consideration of

156 se outcomes, one can carry out either a case-case analysis to investigate etiologic heterogeneity or

157 In the base-case analysis, treatment of CD patients with a steroid-i

158 In the base case analysis, treatment with DT was cost-effective with

159 partum pain management exposures, a complete case analysis, use of an alternative ASD definition, and

160 In the base-case analysis, use of antiseptic-impregnated catheters r

161 er a 12-year period METHODS: A retrospective case analysis using a glaucoma electronic patient record

162 value is estimated by performing a complete-case analysis using a random-effects model that includes

163 tal cost per depression-free day in the base-case analysis was $10 (95% confidence interval, -$13 to

164 The base-case analysis was a cohort of 50-year-old patients.

165 The best-case analysis was based on highest possible intervention

166 The worst-case analysis was based on lowest intervention effective

167 Furthermore, case analysis was carried out to detect driver emotional

168 The degree of bias in complete-case analysis was dependent on simulated factors.

169 A retrospective case analysis was made of patients with AFM treated with

170 To eliminate cost outliers, a best-case analysis was performed by eliminating 50% of patien

171 The base-case analysis was performed for a hypothetical cohort of

172 For our base-case analysis, we assumed a 3-monthly PrEP cost of US$29

173 In our base-case analysis, we assumed that H pylori treatment preven

174 In the base case analysis, we assumed that the sensitivity and speci

175 In a complete case analysis, we fit a linear regression model and acco

176 based on complete case analysis for the base case analysis, where only patients with available EQ-5D

177 stratified risk differences and the complete-case analysis will be unbiased when the stratified effec

178 In the base case analysis with a prevalence of stones of 9%, IOUS wa

179 Complete case analysis with covariate adjustment and multiple imp

180 Hence, complete case analysis with covariate adjustment can and should b

181 Estimates obtained by complete case analysis with covariate adjustment were unbiased as

182 In our base-case analysis with either outcome, MTX continuation, cyc

183 blished fluorescein costs were used for base-case analysis with scenario analysis based on a range of

184 ethods reduced bias compared with a complete case analysis without covariate adjustment.